全文获取类型
收费全文 | 99篇 |
免费 | 11篇 |
专业分类
儿科学 | 5篇 |
妇产科学 | 1篇 |
基础医学 | 12篇 |
临床医学 | 11篇 |
内科学 | 52篇 |
神经病学 | 2篇 |
特种医学 | 2篇 |
外科学 | 5篇 |
眼科学 | 2篇 |
药学 | 6篇 |
肿瘤学 | 12篇 |
出版年
2023年 | 2篇 |
2022年 | 7篇 |
2021年 | 3篇 |
2020年 | 4篇 |
2019年 | 4篇 |
2018年 | 3篇 |
2017年 | 2篇 |
2016年 | 4篇 |
2015年 | 1篇 |
2014年 | 3篇 |
2013年 | 3篇 |
2012年 | 3篇 |
2011年 | 3篇 |
2010年 | 3篇 |
2009年 | 1篇 |
2008年 | 8篇 |
2007年 | 5篇 |
2006年 | 7篇 |
2005年 | 2篇 |
2004年 | 4篇 |
2003年 | 3篇 |
2002年 | 6篇 |
2001年 | 4篇 |
2000年 | 1篇 |
1999年 | 5篇 |
1998年 | 1篇 |
1997年 | 2篇 |
1996年 | 3篇 |
1995年 | 3篇 |
1994年 | 3篇 |
1993年 | 1篇 |
1986年 | 3篇 |
1985年 | 1篇 |
1984年 | 1篇 |
1977年 | 1篇 |
排序方式: 共有110条查询结果,搜索用时 15 毫秒
1.
Inhibitory effects of some MPTP and MPP+ analogues on rat brain MAO activity were studied to further clarify the structure-activity relationships of MPTP neurotoxicity. Of the analogues tested, 4-(4-chlorophenyl)-1,2,3,6-tetrahydropyridine (CPTP), 4-(4-chlorobenzyl)-pyridine (CBP), 4-benzylpyridine (BPY) and 4-benzylpiperidine (BPIP) dose-dependently inhibited both MAO-A and -B activities. CPTP, BPY and BPIP showed a higher MAO-A selectivity, while CBP was a selective MAO-B inhibitor. In preincubation studies, only CPTP greatly enhanced the degree of inhibition of MAO-B when the preincubation time was increased, but inhibition of MAO-A was not enhanced. Together with our previous MPTP and MPP+ analogue findings, the present results indicate that, in these chemical structures, a 4-phenyl-1,2,3,6-tetrahydropyridine ring is most essential for time-dependent inhibition of MAO. This chemical requirement is consistent with the ability to cause nigrostriatal dopaminergic neurotoxicity. 相似文献
2.
3.
4.
5.
Kent E. S. Matlack Daniel F. Tardiff Priyanka Narayan Shusei Hamamichi Kim A. Caldwell Guy A. Caldwell Susan Lindquist 《Proceedings of the National Academy of Sciences of the United States of America》2014,111(11):4013-4018
Alzheimer’s disease (AD) is a common, progressive neurodegenerative disorder without effective disease-modifying therapies. The accumulation of amyloid-β peptide (Aβ) is associated with AD. However, identifying new compounds that antagonize the underlying cellular pathologies caused by Aβ has been hindered by a lack of cellular models amenable to high-throughput chemical screening. To address this gap, we use a robust and scalable yeast model of Aβ toxicity where the Aβ peptide transits through the secretory and endocytic compartments as it does in neurons. The pathogenic Aβ 1–42 peptide forms more oligomers and is more toxic than Aβ 1–40 and genome-wide genetic screens identified genes that are known risk factors for AD. Here, we report an unbiased screen of ∼140,000 compounds for rescue of Aβ toxicity. Of ∼30 hits, several were 8-hydroxyquinolines (8-OHQs). Clioquinol (CQ), an 8-OHQ previously reported to reduce Aβ burden, restore metal homeostasis, and improve cognition in mouse AD models, was also effective and rescued the toxicity of Aβ secreted from glutamatergic neurons in Caenorhabditis elegans. In yeast, CQ dramatically reduced Aβ peptide levels in a copper-dependent manner by increasing degradation, ultimately restoring endocytic function. This mirrored its effects on copper-dependent oligomer formation in vitro, which was also reversed by CQ. This unbiased screen indicates that copper-dependent Aβ oligomer formation contributes to Aβ toxicity within the secretory/endosomal pathways where it can be targeted with selective metal binding compounds. Establishing the ability of the Aβ yeast model to identify disease-relevant compounds supports its further exploitation as a validated early discovery platform.Alzheimer’s disease (AD) is a common and devastating neurodegenerative disorder that is projected to increase in frequency as our population ages. The lack of disease-modifying therapies requires new approaches to address the underlying mechanisms of cellular dysfunction and identify potential therapeutics.The amyloid-β peptide (Aβ) plays a major role in AD and ultimately leads to neuronal death and cognitive impairment (1). Aβ peptides of ∼40 aa are generated by the successive cleavage of the amyloid precursor protein (APP) by β- and γ-secretases. Mutations in APP or γ-secretase cause familial AD and bias APP cleavage toward a 42-aa Aβ peptide that predominates in Aβ plaques, is more aggregation prone, and is toxic to neurons (2, 3). Although Aβ plaques are a common, conspicuous feature of pathology in diseased brains, increasing evidence suggests that small oligomers of Aβ are the most toxic species (4, 5).The conservation of protein homeostasis mechanisms—such as protein trafficking and chaperone networks—among all eukaryotes makes yeast a powerful discovery platform for modeling the cellular toxicities caused by neurodegenerative disease proteins (6). In neurons, the cleavage of APP to generate the Aβ peptide occurs within the secretory and endosomal pathways (7). APP is trafficked through the secretory pathway to the plasma membrane and subsequently internalized and recycled through endosomal vesicles and the trans-Golgi network back to the plasma membrane (7). During this recycling, the Aβ peptide is liberated from APP by β/γ-secretases, thus enabling the peptide to interact with multiple membranous compartments within the cell.We have taken advantage of the great conservation of the secretory and endocytic pathways between yeast and neurons to study Aβ in a simple, highly tractable model organism—budding yeast. By expressing Aβ as a fusion to an endoplasmic reticulum (ER) targeting signal, we have mimicked in yeast the multicompartmental distribution of Aβ (8). This approach bypasses the need to recapitulate the entire APP processing pathway and generates an Aβ peptide with exactly the same sequence as is found in the human brain. The ER targeting signal directs cotranslational transport of the primary translation product into the ER, where the signal sequence is removed by signal peptidase. The peptide then transits through the secretory pathway and is secreted from the cell. In yeast, the cell wall prevents secreted Αβ from diffusing away, allowing it to interact with the plasma membrane and undergo endocytosis. As in the human nervous system (2), the aggregation-prone 42-aa peptide is more prone to forming oligomeric species than the 40-aa peptide (9) and is more toxic (8).This model allowed us to take advantage of yeast genetics to perform a completely unbiased screen of the yeast genome for suppressers or enhancers of Aβ toxicity. Of the ∼6,000 genes we tested, we recovered only a handful of modifiers. There are ∼25,000 genes in the human genome and less than 20 (10) have been shown to confer risk for AD. However, several of the yeast genes that alter Aβ toxicity are either direct homologs or interacting partners of human risk factors (8, 10). For example, YAP1802, is the yeast homolog of PICALM, one the most highly validated risk factors for AD (10, 11); INP52, is homologous to SYNJ1, which interacts with the risk factor BIN1 (12, 13); and SLA1 is homologous to SH3KBP1, which interacts with the risk factor CD2AP (14–16). All of these proteins are involved in clathrin-mediated endocytosis in yeast and humans. In addition to ameliorating the toxicity of Aβ in yeast, these proteins reduced Aβ toxicity in both Caenorhabditis elegans and rat cortical neuronal models (8). The recovery of genes that promote clathrin-mediated endocytosis in unbiased genome-wide screens suggested that Aβ poisons this process (8). Indeed, the peptide compromised endocytosis of a transmembrane receptor (Ste3), an activity crucial for neuronal function. Importantly, the mechanism of action of these risk factors had not previously been linked to Aβ. Thus, the yeast model has already provided key insights on the nature of Aβ’s cellular toxicity in the human brain.In this study, we used our yeast Aβ model to identify small molecules that ameliorate toxicity. In an extremely stringent and unbiased screen of 140,000 compounds, we identified a small number of cytoprotective compounds, including 8-hydroxyquinolines (8-OHQs). Members of this family bind metals and are among the few compounds that have been shown to alleviate Aβ toxicity in mouse models of AD (17, 18), and to show early potential as an AD therapeutic (19). Here, we investigate the mechanism of action for the most efficacious member of this family, clioquinol (CQ). 相似文献
6.
Kojiro Tanoue Hirotsugu Maruyama Yuki Ishikawa-Kakiya Yosuke Kinoshita Kappei Hayashi Masafumi Yamamura Masaki Ominami Yuji Nadatani Shusei Fukunaga Koji Otani Shuhei Hosomi Fumio Tanaka Noriko Kamata Yasuaki Nagami Koichi Taira Toshio Watanabe Yasuhiro Fujiwara 《World journal of hepatology》2022,14(5):992-1005
7.
8.
9.
Noboru Inamura Akio Kubota Ryo Ishii Yoichiro Ishii Yukiko Kawazu Yuji Hamamichi Akihiro Yoneda Hisayuki Kawahara Hiroomi Okuyama Futoshi Kayatani 《Pediatric surgery international》2014,30(9):889-894
Object
The purpose of this study is to evaluate the outcome of our therapeutic strategy for antenatally diagnosed congenital diaphragmatic hernia (ADCDH).Methods
We treated 61 cases of ADCDH according to our strategy. Prostaglandin E1 was required to be maintained the patency of the ductus arteriosus (PDA) in 39 cases (Group I) while it was not administered in 22 cases (Group II). Left ventricular end-diastolic dimension (LVDD) and Tei index were measured with echocardiography on days 0, 2, and 7 after birth. Radical surgery was performed on all cases by day 2.Results
On day 0, Group I showed smaller LVDD and Tei index than those in Group II. Between day 0 and day 2, these parameters increased significantly in Group I, but not in Group II. On day 7, no significant difference in these parameters was observed between the two groups. Five patients died of cardiac and respiratory failure, resulting in a survival rate of 92 %.Conclusion
Our therapeutic strategy improves the clinical outcome of ADCDH. This can be attributed to two factors: earlier surgery resulting in improved LV function. The latter attenuates pulmonary hypertension and maintains PDA with a consequent decrease in right ventricular afterload to compensate for the low cardiac output resulting from PDA. 相似文献10.
Koji Otani Toshio Watanabe Kanae Takahashi Masaki Ominami Yuji Nadatani Shusei Fukunaga Shuhei Hosomi Noriko Kamata Fumio Tanaka Yasuaki Nagami Koichi Taira Tatsuo Kimura Shinya Fukumoto Yasuhiro Fujiwara 《Journal of Clinical Biochemistry and Nutrition》2022,70(2):205
The study group of the Japanese Society of Gastroenterology released evidence-based clinical practice guidelines for chronic constipation (CC) in 2017, and irritable bowel syndrome (IBS) was treated as one of the causes of CC. We examined the differences in characteristics between IBS and non-IBS subjects with CC who underwent a medical check-up in Japan. A total of 10,658 subjects participated in this study, and we focused on 467 subjects who fulfilled the diagnostic criteria of CC using a questionnaire survey. The number of IBS subjects was 21, and they had sleep disorders, were more symptomatic (e.g., abdominal pain, abdominal bloating/distension, feeling stressed, annoyance, lack of motivation, fatigue upon waking, and feeling depressed), and had more episodes of sensation of incomplete evacuation and anorectal obstruction/blockage during defecation than non-IBS subjects. Furthermore, stool frequency of IBS subjects was significantly different from non-IBS subjects. Multivariate ordinal logistic regression analysis revealed that the factors associated with a higher stool frequency were IBS [odds ratio (OR), 2.46; 95% confidence interval (CI), 1.00–6.05; p = 0.049], male sex (OR, 1.97; 95% CI, 1.20–3.23; p = 0.007), and regular exercise (OR, 1.80; 95% CI, 1.05–3.07; p = 0.033). These findings suggest that IBS has unique characteristics in subjects with CC. 相似文献